Fox Chase Therapeutics Discovery Inc (formerly known as Fox Chase Chemical Diversity Center) Announces That It Has Been Awarded a Phase II SBIR From the NIH (NIAID) entitled “Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle”
Doylestown, PA. April 11, 2023 – FCTDI (formerly known as FCCDC) is pleased to announce that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIAID) entitled “Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle” (R44AI152788-03).